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Abstract 
 
Heart disease includes an array of cardiovascular diseases causing 25% of all 
deaths annually in the United States. Patients who live with heart disease experience 
significantly decreased quality of life. While current treatments on the market aim at 
improving heart function and cardiovascular efficiency, none are able to restore 
functionality to native levels. Tissue engineered approaches are becoming increasingly 
viewed as the definitive treatment to increasing longevity and quality of life of patients 
affected by heart disease. While stem cell therapies have immense potential, clinical 
application is still largely unsuccessful in generating healthy myocardium in patients. 
This study aims to differentiate and characterize human embryonic, induced pluripotent, 
and adipose derived stem cells into cardiomyocytes to engineer an electrically conductive 
construct for heart disease patients.   
Action potentials of embryonic, and induced pluripotent derived cardiomyocytes 
were measured using Nanion’s automated patch clamp system in order to attain baseline 
measurements. Current and voltage clamp configurations were used under physiological 
conditions and electrical signals were sampled every 15 seconds. In addition, two and 
three dimensional co-culture studies were performed using adipose-derived and 
embryonic-derived cardiomyocytes. The cells were seeded within an agarose gel and on 
6-well plates at a 2:1 ratio. Samples were then measured using the automated patch clamp 
system after seven days of culture and stained for connexin-43 and desmin using 
immunofluorescence. Lastly, multielectrode array measurements readings were 
performed using embryonic derived cardiomyocytes to verify the patch clamp data.  
 iii 
Results showed differentiated induced pluripotent stem cells produced action 
potentials almost identical to ventricular cardiomyocytes. No action potential readings 
were able to be recorded for the three dimensional cultures, however physiologically 
relevant action potentials were measured in the 2D co-culture groups. Additionally, the 
3D co-culture samples all stained positive for connexin-43 and desmin verifying that the 
differentiated cells possessed unique cardiomyocyte markers. Future studies should 
devote more effort into differentiating successful cardiac pacemaker cells from adipose 
derived stem cells.  
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1 
Chapter 1: Literature Review 
2 
1.1 Structure of the Cardiovascular System 
The cardiovascular system functions to supply nutrients and remove waste from 
tissues throughout the body.  In order to efficiently accomplish this, the conduction 
system is divided into two parts, the systemic and pulmonary circuits. The pulmonary 
circuit serves to oxygenate blood and remove carbon dioxide via the lungs while the 
systemic circuit distributes oxygenated blood to tissues throughout the body. The heart is 
at the center of these circuits functioning as a pump to continually circulate the necessary 
amount of blood. Comprising of two halves, the left side of the heart connects to the 
systemic circuits providing oxygenating blood to tissues while the right side connects to 
the pulmonary circuit disposing of cellular byproduct via the lungs. The heart functions 
through systematic contraction and relaxation cycles able to distribute over 2000 gallons 
of blood per day.1  
Figure 1: Diagram of Systemic and Pulmonary Circuit. 1 
1 Image taken from tes.com
2 Image taken from Interactive-biology.com
3 
1.1.1 Tissue Layers of the Heart Wall and The Pericardial Cavity 
The heart is comprised of three separate tissue layers which structurally reflect the 
physical requirement functionalities that cardiac tissue must undergo. The outermost 
layer is the pericardium which is the membrane encompassing the heart. This is a double 
membrane sac composed of an outmost fibrous layer and an inner serous membrane. This 
encloses the pericardial cavity containing pericardial fluid. The pericardium functions to 
anchor the heart to the mediastinum and prevents the heart from overfilling with blood.  
The serous layer is divided into two layers called the visceral and parietal pericardium 
functioning to prevent friction during repeated cardiac cycles.  
The visceral pericardium corresponds to the outermost layer of the heart known as 
the epicardium. This layer is primarily comprised of fibrous tissue and functions as a 
protective layer.  The middle layer of the heart is comprised of cardiac muscle tissue and 
is the predominate layer of the cardiac wall. The thickness of the myocardium is 
reflective of heavy loads that the heart undergoes to effectively circulate blood 
throughout the body. The innermost layer is the endocardium containing a single layer of 
endothelial cells providing a lining for blood cells coming in contact with tissue surfaces. 
Additionally, this layer also extends to the surface of heart valves as well as providing the 
structure for which the cardiac conduction system is regulated.2
 4 
1.1.2  Chambers and Valves of the Heart 
 
The heart is divided into four chambers each half containing two chambers each.  
The upper chambers are known as the atria while the bottom half of the heart contains the 
ventricles. Each chamber of the heart is separated by heart valves which act as barriers 
between the chambers. The atria is the first chamber of the heart in which blood is 
received from either circuit. The right atria receives deoxygenated blood via the systemic 
circuit while the left atria receives oxygenated blood through the pulmonary circuit. In 
systole, the atria relax and fill with blood which the atrioventricular valves separating the 
atria and ventricle remains closed. Simultaneously, both semilunar valves open and the 
ventricles contract, expelling all contents within the chamber. The atrioventricular valves 
will then open allowing the atria to contract and eject the contents into the ventricular 
chambers. The structure of the chambers is noticeably different as the ventricles have 
substantially thicker walls than the atria. This is due to the elevated forces the ventricles 
receive as the mechanical pressure required to eject fluid out of the heart and through the 
extensive length of the cardiovascular system is much greater than that of the atria which 
only serve to expel fluid to the adjacent ventricles.  
 Furthermore, the valves play an important role in maintaining correct fluid flow 
throughout the cardiovascular system. The valves prevent backflow between chambers 
which would impede the hearts ability to efficiently eject blood. The atrioventricular 
valves contain leaflets that are attached to papillary muscles via chordae tendineae 
preventing the valves from inversion. Similarly, the semilunar valves prevent backflow 
from the arteries into the ventricles. However unlike the atrioventricular valves, the 
5 
leaflets do not have attachments to the heart muscle as they function as a valve similar to 
a vein.2 The structure of the atria and ventricles as well as the valves can be observed in 
figure 2.  
2
     Figure 2: Diagram of the Heart 
1.1.3  Cardiac Conduction System of the Heart 
In order to pump blood efficiently, the heart contains its own unique cardiac 
conduction system. The atria and ventricles must contract at precise temporal intervals 
otherwise blood cannot be properly ejected from the heart. The cardiac conduction 
system is designed such that electrical signals travel from the base to the apex of the heart 
with appropriate delays in signal between specific junctions. The conduction system is 
comprised of the sinoatrial node, atrioventricular node, the bundle of His and the purkinje 
fibers that extend throughout the apex of the heart. This system carries the initial impulse 
which stimulates the entire myocardium extending out to the epicardium.  
2 Image taken from Interactive-biology.com
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To initialize a signal, specialized cardiac muscles cells within the sinoatrial node 
(SA node) located in the wall of the right atrium initialize the electrical impulse by 
sending a signal to the atrioventricular node (AV node) located in the interatrial septum 
via internodal pathways. The signal then continues down through the left and right bundle 
branches to the apex of the heart via the purkinje fibers. Electrical impulses travel at 
varying velocities throughout this pathway to maximize stroke volume. The time elapsed 
for signal travel between the SA and AV node is much longer than signal travel time of 
the bundle branches and purkinje fibers (approximately 0.5 m/sec vs 4 m/sec).3 This 
signal delay allows for complete depolarization of the atria resulting in proper emptying 
of atrial contents into the ventricles. Insufficient delay would cause simultaneous 
contraction of the atria and ventricles resulting in improper emptying and backflow. In 
addition, atrial and ventricular pathways are only connected through the AV node, which 
acts as a buffer preventing improper signal propagation between atria and ventricles. This 
pathway can be viewed in figure 3. 
Figure 3: Diagram of the Cardiac Conduction System3 
3 Image taken from Boundless.com 
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1.2 Cellular Anatomy of Cardiomyocytes 
1.2.1 Varieties of Cardiomyocytes 
There are two main types of myocytes found in the heart which distinguishing 
characteristics. The majority of cells in the myocardium are non-spontaneous which are 
present in both the atria and ventricles. These cells have the capability of propagating 
electrical signals however they are unable to spontaneously contract. The second type of 
cell is a cardiac pacemaker cell. These cells have special transmembrane proteins that 
allow them to spontaneous contract thus exciting neighboring cells creating an action 
potential that is carried throughout the myocardium. Most cardiac pacemaker cells are 
located in the SA and AV nodes and thus are responsible for generating an electrical 
impulse. 
Muscle contraction due to signal conduction can only be achieved due to unique 
properties of cardiomyocytes on a cellular level. The anatomy is a direct representation of 
the rigorous environment of the cell. On a microscopic level, cardiomyocytes appear to 
be a branching, interconnected network of cells more rectangular in appearance from the 
spindle shaped smooth muscle cells and smaller in length and width from skeletal muscle 
(0.1 mm by 0.2 mm).  
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Figure 4: Microscopic image of cardiomyocytes zoomed 
to show detail of  intercalated discs4 
Cardiomyocytes contain a single nucleus, yet multiple mitochondria, providing 
additional energy for many cycles of cellular contraction. Furthermore, striations can be 
viewed under the microscope as light and dark bands in parallel arrangements of actin 
and myosin throughout the cell. However, the most defining features that separate 
cardiomyocytes from other cells are the presence of intercalated discs (figure 4) which 
comprise a variety of cellular junction that serve a variety of different functions. 
Intercalated discs are classically understood to have three main functional zones: the 
fascia adherens, desmosomes and gap junctions.4 
1.2.2 Intercellular Junctions in Cell Signaling 
The fascia adherens transmits mechanical forces between cells and provides an 
anchor site for actin filaments to attach to proteins within the fascia adherens. 
Additionally, this region contains catenin proteins which allows for cadherins to attach 
forming multiple intracellular contacts. Coupled with this subcellular domain are 
4 Image taken from humanpathology.com 
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desmosomes comprising the second zone which act as a “glue” preventing cellular 
separation during contraction through robust bonding of intermediate filaments between 
cellular cytoskeletons. Furthermore, the third and most critical regions are comprised of 
gap junctions, providing a means of transcellular signaling that provides the platform on 
which transmitting electrical signals are possible. Gap junctions narrow the space 
between adjacent cells from approximately 25 nm to 3 nm at the site of the junction 
proteins. These domains are made up of ion channels known as connexons 
(predominately Cx40 and Cx43) which form a pore through precise alignment of the Cx 
proteins between adjacent cells. Typically six connexins are present at each intercalated 
disc which allow for ample passageway between cells to propagate strong action 
potentials across cell membranes via ion transfer (Na, K, Ca).4 
1.2.3 Cellular Contraction and The Sliding Filament Model 
In cardiac muscle, contraction occurs through what is known as excitation 
contraction coupling. This process converts an electrical stimulus to a mechanical 
response. Excitation contraction coupling is dependent in cardiac muscle tissue on an 
event called calcium induced calcium release (CICR) by which the presence of calcium 
ions further stimulate the release of calcium ions.  
When an action potential is generated, sodium influx through the cell membrane 
and into t-tubules stimulates the activation of a receptor called dyhydropyradine channel 
or commonly known as L-type calcium channel. Increased concentration of sodium ions 
activates this channel to open allowing calcium to enter the cell. As a result of elevated 
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intracellular calcium levels, ryanodine channels in the sarcoplasmic reticulum are 
activated and additional calcium is transported into the cytosol.  
Increased intracellular calcium levels is critical in muscle contractions and 
especially when creating a sustained contraction as seen in the ventricles. Calcium 
activates contraction by binding to troponin on the actin filament. Tropomyocin a helical 
protein wrapped around actin is released and the myosin binding sites are exposed for the 
myosin head to attach. Upon adenine triphosphate hydrolysis the myosin head contracts 
pulling the actin across laterally. This reaction takes place at many different locations and 
collectively is able to stimulate an entire fiber to contract. This is shown in figure 5 and is 
known as the sliding filament model.5  
Figure 5: Diagram of the sliding filament model5 
1.3 Electrophysiology of the Cell 
1.3.1 Voltage Gated Ion Channels 
Electrically excitable cells must all possess conduits in which electrical current 
may flow. When speaking in terms of cellular physiology, electrical current manifests 
5 Image taken from thealevelbiologist.co.uk 
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itself through positively or negatively charged ion flow. To achieve ample ion transfer 
between cells cardiomyocytes possess special structures for cell to cell contact as 
discussed previously as well as voltage gated ion channels that allow for the transfer of 
extracellular ions.  
The most predominate voltage gated channels found on most electrically excitable 
cells are sodium and potassium channels. These channels are integral membrane proteins 
comprised of alpha and beta subunits spanning six membrane-bound segments as shown 
in figure 6. The S4 segment is highly conserved and is responsible for sensing the voltage 
within the channel. When stimulated by a transmembrane change in voltage, this unit 
moves slightly towards the extracellular side of the membrane to become more permeable 
to ion flow.  
Figure 6: Voltage gated ion channel domains spanning the cell 
membrane6 
There are three states of voltage gated ion channels: closed, open, and inactivated. 
The state of the channel is dependent upon the voltage of the environment as the channels 
6 Image taken from Nature 
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will open or close in response to a change in transmembrane voltage. Inactive states are 
those which can be seen at the peak of an action potential where a channel will plug the 
lumen to prevent further ion flow. Furthermore, ion channels posses selectivity filters that 
are composed of negatively or positively charged amino acids depending on the channel 
type. Sodium channels often have negatively charged residues to attract the positively 
charged sodium. Channels are additionally size selective to restrict ion flow. Sodium 
channels do not allow potassium or calcium ions to pass as the pore diameter is too 
small.4
In the case of pacemaker cells, specialized membrane proteins allow the cell to 
excite itself without the need for external stimulation. This occurs due to leaky sodium 
channels that allow the steady passage of sodium through the cell causing the initial 
change in membrane potentials. Additionally, antiporter proteins known as the sodium-
calcium exchanger (NCX) operates by using the electrochemical gradient found in the 
extracellular solution to allow sodium ions to flow intracellularly in exchange for 
extracellular transport of calcium ions. The NCX transports one calcium ion for every 
three sodium ions thereby resulting in a net positive influx of positive charge. This causes 
the cell to further depolarize itself until it reaches a set voltage in which an irreversible 
and complete depolarization occur. The NCX also has the ability to reverse transportation 
and does so briefly following each action potential as intracellular sodium concentration 
must be reduced and calcium increased until L type calcium channels are activated.6 
However, calcium concentration is not as high as a typical cardiomyocyte since 
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pacemaker cells do not need to sustain mechanical contraction and is reflected in the 
action potential which can be seen in figure 7. 
Figure 7: Action potential diagram of a cardiac pacemaker cell7 
1.3.2 Stages of Action Potentials in Cardiomyocytes 
In ventricular cardiomyocytes, action potentials are unique in that constant 
voltage in necessary in sustaining contraction between cells. Unlike action potentials of 
neurons or cardiac pacemaker cells, the action potential is drawn out due to CICR which 
can be seen in figure 8. Classically, there are five regions of the cardiomyocyte action 
potential (labeled 0-4) which represents the main stages in generating the action potential. 
7 Taken from classes.midlandstech.edu 
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Figure 8: Action potential of a ventricular cardiomyocyte8 
All electrically excitable cells have a resting membrane potential due to the 
different concentration of ions across the membrane potential which is represented by 
stage four in the graph. Typically, sodium ions are present in higher in extracellular 
concentrations and conversely, potassium ions are more abundant in the intracellular 
space. However, the ratio of sodium to potassium ions across membrane is not 1:1 and 
therefore a resulting charge is placed across the membrane. Due to a much higher 
concentration of sodium across the membrane, as seen in ventricular cardiomyocytes, 
resting membrane potential is set at around -90 mV.  
Action potentials are generated when ion concentration changes from its natural 
levels causing a rapid change of membrane potential. Phase 0 in the graph represents an 
influx of sodium ions into the cell resulting in a rapid depolarization of the membrane. 
Action potentials are unidirectional, irreversible and are typically known as all or nothing 
events because once transmembrane voltage reaches a certain threshold, complete and 
8 Image taken from pathophys.org 
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rapid depolarization occurs. Once transmembrane voltage reaches -50mV due to rapid 
sodium influx, repolarization begins to occur as potassium and chloride ions move out of 
the cell reducing intracellular charge, this happens slowly and potassium efflux occurs 
over the course of phases 1 and 2.  
Phase 2 is the most notable and unique in that a sustained calcium influx occurs in 
response to L-type calcium channels opening as a result of extreme depolarization and an 
outward efflux of potassium ions. The final stage is repolarization which results from 
calcium channels closing and a delayed rapid potassium efflux across the membrane 
dropping the membrane voltage back to its resting potential. As this process occurs, ion 
movement flows both across the cell membrane and between cells through connexins 
causing the propagation of action potentials throughout the myocardium.7 
While all cardiomyocytes are able to respond and propagate action potentials, 
action potentials generated by ventricular cardiomyocytes are substantially different than 
those seen in cardiac pacemaker cells as illustrated in figure 7. While ventricular 
cardiomyocytes must sustain contraction for complete blood ejection from the ventricle, 
pacemaker cells must provide the initial signal for ventricular cells to respond. While 
pacemaker cells contract on some level, they do not contract on the magnitude of 
ventricular cardiomyocytes, hence a lack of a plateau upon depolarization. Additionally, 
these cells have a much slower initiation due to slow depolarization via the NCX protein 
and thus a much longer phase 4 region as can be viewed in image 7.  
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1.3.3 Modeling Electrophysiology Using Circuitry 
The paradigm of modern electricity to the layperson consists of a circuit 
composed of various components that acts as a conduit for electrons to pass through. 
However many cells in the body also act as circuitry to perform many critical functions 
for survival. Neural networks of cells pass billions of signals daily to perform motor or 
sensory functions. Cardiac cells transmit current to pump blood throughout the body. 
Regardless of cell type or function, all electrically excitable cells can be modeled using 
traditional circuitry diagrams.  
In electrophysiological modeling, resistors are used to model ion channels 
through which ions or current flows as shown in figure 9. It is convenient to discuss 
currents as conductance (the inverse of resistance) as conductance sums in parallel 
circuits. When modeling several ion channels open simultaneously, the total conductance 
is simply the sum of all individual channel conductances. Additionally, the cellular 
membrane acts as a capacitor due to the membrane thickness, and its good insulator 
properties.  
             Figure 9: Physical representation of a circuit modeling the cell membrane9 
9 Image taken from Axon Patch Clamp Guide 
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Capacitance is defined as the ability to store charge when a voltage is present 
between two points. In terms of cellular electrophysiology, capacitance can be neglected 
when voltage remains constant across the membrane. If voltage clamping, transient 
capacitance currents can be measured for a brief time while stepping up to a new voltage 
value, appearing as an artifact in the graph.   
Establishing directional conventions for vector measurements is crucial when 
measuring action potentials. Voltage defined by the electrical potential with respect to 
one spatially defined position can be represented using a battery which can be reversed 
depending on the microstate of the cell at any given time. Voltage can be applied globally 
across the cell membrane or locally through any given ion channel. For example, 
measuring a cardiomyocyte sodium channel in a grounded state where extracellular 
sodium concentrations are approximately 10 fold higher than intracellular concentrations 
would approximate to a +90 mV battery in a physiological normal cell. Conversely 
potassium channels in a resting state would equate to approximately -90 mV in 
physiologically normal cells.8 When discussing the resting membrane potential, defined 
as voltage of the inner membrane with respect to the outer membrane in an unexcited 
state, it is important to remember that this condition represents a steady state system in 
which no net ion flow occurs across the membrane. Furthermore, representing positive 
ion influx across the cell membrane is conventionally established as negative current. 
Conversely, positive ion efflux through the membrane would be considered positive 
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current. If voltage clamping a mature healthy cell, one would expect to see a large 
negative current followed by a positive current until complete repolarization occurs. 
1.3.4 Using Patch Clamping Techniques to Characterize Cellular 
Electrophysiology 
Measuring action potentials in cells has been around since the late 1940s when 
giant squid axons were voltage clamped to measure trans-membrane current. These 
experiments were the foundation for Hodgkin and Huxley’s action potential model and 
became the basis for cellular electrophysiology. Since then, measuring action potentials 
has become more refined and precise since the development of the patch clamp 
technique.  
Patch clamping was developed in the late 1970s and into the early 80s by Erwin 
Neher and Bert Sakmann who later went on to receive the Nobel Prize in Physiology and 
Medicine in 1991. This laboratory technique allows high-resolution current recordings of 
single or multiple ion channels on cell surface membranes. Since its inception, there have 
arisen many variations on this technique but in principle its recording methodology 
remains unchanged.  
The traditional or cell attached patch clamp technique is used to study single ion 
channels or a small patch of channels on the cell surface membrane As evidenced in 
figure 10, a glass micropipette filled with bath solution is placed on the cell membrane 
and suction is applied to form a highly resistant seal in the gigaohm range. This tight seal 
is essential in insulating the cell patch as all ions must flow from the ion channel into the 
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pipette tip. Ion flux is measured using a silver chloride electrode connected to an 
operational amplifier and a bath electrode is used as a reference node. 
Once the setup is complete, the user may clamp the current or voltage at the 
desired level depending on the cell type. If clamping the voltage, the user inputs the 
appropriate voltage and the membrane voltage will be measured and compared to the 
input voltage. If the two values are different, the amplifier will inject current into the cell 
until the membrane potential equals the user input voltage. Conversely, when measuring 
action potentials current is clamped and through the same process, voltage is measured 
across the cell membrane.  
Figure 10: Traditional patch clamp setup diagram10 
There are a couple of variations of the cell attached patch clamp method including 
the inside out and outside in patch clamping techniques. The inside out patch involves 
removing a section of membrane from the cell using the pipette tip. In this way, the 
researchers are able to access the intracellular surface of the membrane via the bath and 
manipulate the composition that the membrane is exposed to. This technique is very 
10 Image taken from axiogenesis.com 
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useful when changing the environment at the intracellular domain of specific ion 
channels.  
The outside in patch clamp is the reverse of the inside out method and is used 
when attempting to manipulate the extracellular domains of the ion channels. This 
method is accomplished by slowing removing the pipette tip from the surface of the cell 
membrane once a gigaohm seal is formed. If done correctly, once a small patch is 
separated from the membrane, the pieces should reattach itself as a bulb at the end of the 
pipette tip allowing for measurements of a single ion channel while manipulating 
chemical composition of the external bath. 
The cell attached patch clamp method and their derivatives are only used when 
studying individual ion channels. For researchers seeking ion flux over the entire cell, 
this technique would be inappropriate as it only quantifies the flux through one or a few 
channels. Thus there have been variations on this method to allow for the measurement of 
action potentials. While the overall theory behind the cell attached clamp remains 
constant, minute changes in how the pipette tip is applied to the cell will change the 
magnitude of the measurement.  
The most common method for quantifying whole cell electrophysiology is 
through a variation on the cell attached clamp called the whole cell patch clamp. The 
main difference between these methods is the application of the pipette tip. In the whole 
cell patch method, the pipette tip is applied anywhere on the cell membrane surface. A 
vacuum is applied to the pipette until the cell membrane tears. The cell can then be 
stimulated and the electrode is able to measure the ion flux through the entire cell.  
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Figure 11: Variations on the patch clamp technique11 
While traditional patch clamping methods are necessary depending on the area of 
interest and cell type, there are many variations on this method that have been developed 
to increase efficacy and speed of the research. One of the most recent developments in 
patch clamping is the automated patch clamp which provides researchers with a much 
more streamlined method of measuring electrophysiology of cells and allows 
accessibility to those without prior patch clamping experience.  
The automated patch clamp is a single machine that uses a vacuum to break the 
cell membrane and an internal electrode to stimulate and measure electrophysiological 
response. Researchers simply need to apply intracellular solution inside the chip, 
extracellular solution outside of the chip along with the cell suspension. Once the vacuum 
is turned on, cells in suspension will be dragged downward onto a perforated chip 
fabricated with a micro-hole approximately 1-2 um in diameter. Once a single cell lands 
on a hole along the chip, the seal is created and the vacuum will increase to break a tiny 
section of the cell membrane. Voltage or current can then be measured across the whole 
cell.  
                                                
11 Image taken from microsystems.com 
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Unfortunately, while this system is incredibly convenient for the average user, it 
is limited in its application. This method is only valid if recording current or voltage 
throughout the entire cell as the automated method is not precise enough to measure 
specific ion channels on the cell surface membrane. For studies involving cellular 
response to drugs or inhibitors, certain ion channels must be isolated which is only 
possible using the manual patch clamping method. Additionally, this method can only be 
used with cells of geometries favorable to forming a high resistive seal. Spindle shaped or 
amorphous cells such as fibroblasts or neurons would likely not form a gigaseal and thus 
would allow residual ions to pass between the chip and the membrane. In addition, cells 
smaller than 2 um in diameter cannot be used for this method since they would be 
vacuumed through the hole in the chip.  
Figure 12: Microchip diagram of the automated patch clamp12 
While patch clamp offers many benefits to running patch clamp experiments, 
there are often many setbacks in doing so. Apart from the automated patch clamping 
method, getting accurate action potential readings using traditional setups are extremely 
time consuming and difficult. Since measuring any electrophysiological activity on the 
12 Image taken from discoverymedicine.com
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cell requires direct contact between the cell surface and a pipette tip there are many 
physical limiting factors in forming a tight seal. Cells must have an appropriate geometry 
as the pipette is limited in its angle when approaching the cell. Cells that are too flat and 
spread widely over the surface of the plate make it very difficult to allow for appropriate 
contact with the pipette tip. Furthermore, the pipette tip must have perfect geometry, as 
any imperfections would lead to piercing of the cell membrane or the inability to form a 
highly resistive gigaohm seal.  
In addition to dimensional problems when performing patch clamp 
experimentation, there are also physical limitations when applying any stimuli to the 
cells. Oftentimes it is difficult to achieve accurate action potential measurements as it 
becomes more difficult and less precise to maintain a constant current throughout the cell. 
Voltage gated ion channels are the limiting factor to current flow as these conduits are 
only responsive to changes in voltage. Thus, with the exception of a brief charging time, 
ion channels will not open in response to continuous ion flow. Therefore, cellular 
recordings of action potentials are limited to a few samples before the membrane ruptures 
and cellular death takes place. While voltage clamping offers superior user flexibility, 
current clamping mimics the processes found in nature and thus is more applicable when 
characterizing electrophysiology capacity of stem cell derived cardiomyocytes.8,9
1.3.5 Using Multi-Electrode Arrays to Characterize Cellular Electrophysiology 
Multi-electrode arrays (MEAs) are geometrically fixed arrangements of electrodes 
that record and monitor electrophysiological signals. The first in vitro arrays to measure 
cell culture monolayers was in the 1950s to measure signals from myocytes extracted 
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from chick embryos. Since then, MEAs have expanded in their form and approach and 
can be applied to in vitro and in vivo studies.  
The most commonly used MEAs are those for single layer cell culture 
experiments. For studies that involve recording whole cell or tissue culture 
electrophysiology, MEAs have become increasingly popular due to their ease of use and 
practicality. The setup of a traditional in vitro MEA setup consists of four primary 
components: the MEA chip, amplifier, data acquisition hardware, and data visualization 
and analysis software. The MEA chip consists of a glass well that contains a grid of 
electrodes that vary in spacing, size and material. Standard electrode dimensions and 
quality usually consist of titanium nitride coating with diameters ranging between 10-30 
microns. Additionally, inter-electrode spacing can vary between 100-500 microns. 
Typically a 8 x 8 grid of 60 electrodes is most commonly used however the number of 
electrodes can vary significantly depending on the application. Electrode quantity and 
special dimensions are solely dependent on desired sampling rate and the quality of the 
tissue. For delicate neural networks or small specimens, finer geometric tolerances are 
desirable to achieve a more precise measurement. Conversely, for large-scale analysis of 
a sample culture, wider intranodal spacing is appropriate. 
To perform electrophysiological readings, cells must be cultured on the MEA chip 
until fully mature. Once cells are visibly contracting, the MEA plate can be seated in the 
amplifier to be read by the data acquisition software. The electrodes transduce the change 
in voltage through the variation in ion concentration and converts into an electrical 
current carried by electrons. The data acquisition software is able to record the voltage 
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changes over time for each electrode and outputs the results in a grid in which each box 
displays an action potential measured by the corresponding electrode on the MEA plate. 
Measuring action potentials using MEAs are oftentimes the preferred method as 
patch clamping is a long and arduous process that often fails to achieve meaningful 
measurements if conditions are less than perfect. However one drawback with using a 
basic MEA setup is that the cells must be spontaneously contractile. Since basic MEA 
setups lack a stimulus that can be applied to cells, non-pacemaker cells while capable of 
producing an action potential, will not be measured since there is no spontaneous flow of 
ions. Advanced setups may be used to stimulate non-spontaneous cells however it can be 
difficult to achieve an efficient way of stimulating myocyte like cells, thus external 
stimuli are typically reserved for use in stimulating delicate neural networks.10  
1.4 Pathologies of the Cardiovascular System 
1.4.1 Atherosclerosis and Myocardial Infarction 
Myocardial infarction or commonly referred to as a heart attack is when there is 
an occlusion of the coronary arteries. These arteries supply blood to the heart itself 
extending as a branch of the aorta down to apex of the heart. When the artery becomes 
occluded, the heart may either develop a severe arrhythmia or extensive tissue damage 
will result depending on the severity of the blockage and the period of time in which the 
artery is obstructed. In almost all cases, myocardial infarction occurs in patients that have 
advanced stages of atherosclerosis.  
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Atherosclerosis affects upwards of 25 million people each year in the United 
States contributing to a bevy of various cardiovascular diseases.11 Atherosclerosis begins 
at birth and progresses throughout the human lifespan more or less aggressively 
depending on a variety of different factors including diet, exercise, smoking, alcohol, 
genetics, etc. Depending on the region in which atherosclerosis takes place will determine 
the pathology and progression of this disease. The composition of the coronary arteries is 
such that it is able to withstand high pressures due to large stroke volumes. 
While atherosclerosis in the coronary arteries is one of the primary causes of heart 
attacks, it doesn’t have to take place within the coronary arteries. Atherosclerotic plaques 
from any vessel in the body are able to embolize within the bloodstream and flow into the 
coronary arteries forming an occlusion. Additionally, any thrombus formed in the 
vasculature due to cardiovascular implants are able to detach due to wall shearing 
forming an embolus that could also get lodged within the coronary arteries. In most cases, 
about 70% of all patients who suffer from myocardial infarction survive with a 5 year 
survival rate of about 30%12. The largest factors determining the outcome of patient 
survival are the time in which the patient gets treated. However patients who are unable 
to receive treatment within 45 minutes, results in irreversible damage. Prolonged 
ischemia results in necrosis of cardiomyocytes resulting in a significantly weaker area of 
the heart. Typically the ventricles (the left ventricle being the most common) are the 
regions of heart most effected due to upstream occlusion. Thus, the result of severely 
damaged tissue in the ventricular areas lends itself to a variety of fatal side effects most 
predominantly are mechanical problems. 
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Since cardiomyocytes are a non-regenerative tissue, any damage created is 
irreversible and cannot be healed in the same way a lesion would on the epidermis. In the 
case of cardiomyocytes, diseased tissue becomes replaced with scar tissue, significantly 
reducing functionality. Fibrous tissue is composed predominately of fibroblasts that have 
a significantly lower modulus of elasticity resulting in a stiffer material compared to 
muscle cells. Hence, when extensive necrosis occurs in the ventricles, healthy 
cardiamyocytes secrete fibrin and collagen to replace the damaged tissue. As a result, the 
ventricles are unable to contract with an even circumferential force resulting in a lower 
stroke volume ejected through the systemic circuits. In addition, fibrous tissue does not 
have the elasticity of healthy muscle tissue which results in dilation of the ventricle.13
Figure 13: Image of dilated ventricles post myocardial 
Infarction13 
Consequently, the damaged ventricle compensates for a loss of functionality and 
thus cardiomyocytes will hypertrophy in response to an increased load. If not corrected, 
cardiomyocytes will continue to hypertrophy until the entire heart becomes swollen 
leading to further mechanical problems. Thus to prevent this chain of pathological events 
13 Image taken from path.upmc.edu
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from occurring, it is critical to implement treatments that reduce the stresses on the heart 
and ultimately find a solution to replace diseased tissue with healthy functioning 
cardiomyocytes. 
1.4.2 Pathologies of the Cardiac Conduction System 
Cardiac arrhythmias are one of the most common cardiovascular pathologies 
globally that affects over 14 million people a year in the United States alone. There are 
many different varieties of arrhythmias which is used as an umbrella term for any subset 
of conditions in which the heart beats too fast or slow. Arrhythmias are typically 
measured and diagnosed using an electrocardiogram (EKG or ECG). The contraction of 
the heart is visualized using a waveform in which is subdivided into four sections each 
corresponding to a unique event in the cardiac cycle. An example of an EKG of a healthy 
person is shown in figure 14. The p-wave corresponds to the atrial contraction and is 
shortly followed by the QRS complex representing ventricular depolarization and 
contraction while the T wave represents ventricular repolarization. The PR interval 
indicates the transit time between the SA and AV node and similarly the QT interval 
indicates the time for the ventricles to contract and relax.  Arrhythmias can be quickly 
diagnosed by visualizing an abnormal waveform and will vary depending on the type of 
arrhythmia.14  
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Figure 14: Normal EKG diagram displaying peaks 
and intervals14 
There are four main types of arrhythmias: premature atrial and ventricular 
contraction, supraventricular tachycardias, ventricular arrhythmias, and bradyarrythmias.  
Premature atrial and ventricular contractions occur when another region of the atria or 
ventricle contracts before the SA/AV node. This triggers a premature heartbeat that 
occurs in healthy individuals of all ages and does not necessarily indicate a predisposition 
to a heart condition. They are typically perceived as a feeling a skip in heartbeat or a 
pause between heartbeats and are the most prevalent type of arrhythmia. No medical 
treatment is necessary unless irregular beating continues.  
Bradyarrhythmias are the opposite of tachycardia arrhythmias in that they are 
conditions in where the heart rate is slower than the normal resting rate of 60 beats per 
minute. This condition is caused from a number of variables ranging from lifestyle to 
nodal irregularities. Commonly, the cause results from impairment in the ability of signal 
propagation to occur from one of the nodes. Oftentimes athletes have resting bradycardia 
due to high training intervals where the heart is being over exerted. Bradycardia 
14 Image taken from chicagomedicalcenter.com
30 
oftentimes goes untreated especially if the resting heart rate doesn’t drop below 50 beats 
per minute and is not considered a life threatening condition.  
Supraventricular tachycardia (SVT) is an arrhythmia occurring when typically the 
SA node sends signals sporadically and at varying time intervals. Common conditions 
such as atrial flutter and fibrillation are all categorized as SVTs. It manifests itself in an 
accelerated heart rate and many irregular signals are blocked at the AV node which can 
be viewed as an increased peak of the P wave as shown in figure 15. Fortunately this is a 
less serious condition as the AV node acts as a safeguard allowing only a small fraction 
of these misfires to pass. Thus normal contraction of the ventricles allows for a proper 
ejection of blood and is not life threatening if diagnosed and treated at onset.  
Figure 15: EKG of a patient with supraventricular 
tachycardia15 
Ventricular arrhythmias are less common but can be lethal if not treated 
immediately. This is caused by premature contractions of the ventricles due to other 
regions firing independently of the AV node. This condition is the most obvious 
abnormality on an EKG and has a varying waveform with broad QRS complexes as 
15 Image taken from chicagomedicalcenter.com
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shown in figure 16. Patients often experience chest pain, rapid heartbeat and dizziness or 
nausea.15  
Figure 16: EKG of a patient with ventricular tachycardia16 
1.4.3 Current Treatment Options for Patients with Heart Disease 
There are a number of options available for patients who suffer from myocardial 
infarction. Depending on the extent of the tissue damage and the age of the patient among 
other factors will determine the course of treatment. One of the most common procedures 
performed in patients who are known to have advanced atherosclerosis is a coronary 
artery bypass graft (CABG). CABG is a procedure where a section of healthy artery or 
vein is removed somewhere from the body (mammary artery/saphenous vein) and is 
stitched from the aorta, or a branch of the aorta, past the occluded region in the coronary 
artery (referenced in figure 17) 
Depending on the extent of plaque buildup in the coronary arteries will determine 
whether multiple grafts will have to be made during surgery. One shortcoming with this 
procedure is finding veins or arteries suitable for grafting. Oftentimes, if atherosclerosis 
has advanced significantly where the patient needs multiple CABG’s the accumulation of 
plaque is also found in the vessels desirable for this grafting procedure. Thus, CABG may 
16 Image taken from chicagomedicalcenter.com
32 
not be an option for patients with very progressive atherosclerosis. In addition, this 
treatment does nothing to address the problem of restoring functional properties of 
cardiac muscle tissue to the scarred areas of the ventricles post MI. While this course of 
treatment is successful in preventing future MI’s, it doesn’t address the damage that has 
already been done.  
Figure 17: Diagram of a CABG procedure17 
CABG patients are still as risk for a number of mechanical failures. As detailed 
previously, scarred regions of the heart are significantly weaker than cardiac muscle 
tissue and as a result of being exposed to extreme pressures of the ventricle, patients are 
at risk for ventricular aneurysm. To prevent this from happening, surgeons will often 
perform an endoventricular circular patch plasty (EVCPP) concurrently with a CABG 
procedure. This procedure entails making an incision down the scarred region of the 
ventricle, stiches are sewn around the infarct area and finally the stiches are pulled 
together closing the ventricle. This eliminates the risk of an aneurysm or rupture of the 
ventricular wall, thus reducing the dilation of the left ventricle. In addition this procedure 
is also shown to have improved left ventricular ejection compared to CABG alone. 
17 Image taken from mountsinai.org
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Unfortunately, this treatment has not shown to significantly improve mortality rates in 
patients.16 
Another course of treatment that is common for patients post MI is a left 
ventricular assist device (LVAD) (Figure 18). This device is a pump connected to two 
tubes that suture from the left ventricle to the aorta. This device addresses the mechanical 
deficiencies of the heart post MI however this course of treatment is not without its 
shortcomings. While LVADs significantly alleviate stresses on the ventricle, patients 
must remain on anticoagulants for the rest of their life to reduce the risk of rejection22. 
Additionally, up until recently, older models of this device were large and bulky and 
required the patient to wear a backpack housing the external battery to the device. 
Current models emerging on the market now are significantly smaller and can be charged 
externally so as not to have any wires protruding from the body to power the LVAD. 
Furthermore, the impeller inside the pump is prone to expose blood cells to excess 
shearing causing the patient to essentially lose healthy blood cells. Improvements in the 
impeller design are currently in development to reduce turbulent flow of the blood cells 
contacting impeller edges thereby reducing cell shear.17 
 
Figure 18: LVAD implantation and technical diagram  
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illustrating components and device placement18 
For patients with arrhythmias, there are a number of treatment options depending 
on the type of arrhythmia. For patients with less serious arrhythmias originating above 
the AV node simple physical maneuvers have been found to be successful in blocking 
conduction thorugh the AV node by increasing parasympathetic nervous supply to the 
heart via the Vagus nerve. Vagal maneuvers include gagging, holding ones breath or 
coughing to slow the heart rate.  
When physical maneuvers are insufficient in reducing heart rhythm, drugs may 
become necessary. Some drugs prevent arrhythmias by interfering with sodium and 
potassium gated ion channels while others function by acting as anti-parasympathetic 
nervous system agents. There are many drugs on the market that are very specific 
depending on the subset of arrhythmia the patient is diagnosed with. They are generally 
very successful as a prolonged treatment option and are implemented whenever possible 
as it’s non-invasive and has good patient outcome.  
For patients with life threatening arrhythmias that cannot be sufficiently treated 
using the discussed options, more drastic and invasive measures must occur. Patients who 
have ventricular fibrillation leading to cardiac arrest require defibrillation. Defibrillation 
consists of providing a high dose of current directly to the heart. By administering a high 
external current, the cardiac conduction system can reset and return to normal sinus 
rhythm. Defibrillators come in many varieties and can be external or implantable. 
Automated External Defibrillators (AEDs) are most common and can be used by the 
18 Image taken from stanfordhealthcare.org
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layperson and can be found in public access places. AEDs involve attaching electrode 
pads to the patients chest and pressing a button to deliver a high voltage shock to the 
patient. This may be repeated numerous times as necessary and is found to significantly 
increase survival rates with cardiac arrest patients surviving close to 40% of the time as 
opposed to 0% with no defibrillation. Additionally, implantable defibrillators are 
common in patients with a medical history of ventricular fibrillation as these implants can 
detect the fibrillations and signal an immediate impulse to the heart.18
Similar to defibrillators, the most common implantable device for correcting 
arrhythmias are pacemakers. These are commonly used for patients with bradycardia 
where recovery is unexpected or for patients recovering from MI. Modern pacemakers 
are programmable and allow the cardiologist to tailor the settings to the patients 
condition. Pacemakers can either be singular or biventricular and can monitor and 
provide pacing for both atrial and ventricular arrhythmias which are common in heart 
failure patients. They comprise of three components: a pulse generator, leads and 
electrodes on the end of each lead. The pulse generator is implanted below the collarbone 
and the leads are snaked through a large vein to the interior of the heart where they rest 
on the heart wall. The electrodes can monitor the beating and provide a signal if any 
abnormalities are detected.19 A modern defibrillator and positioning can be viewed in 
figure 19. 
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Figure 19: Diagram of pacemaker with placement 
of biventricular leads19 
1.5 Cardiac Tissue Engineering and Regenerative Medicine 
1.5.1 Approaches to Cardiovascular Regenerative Medicine 
There are two current methodologies that are under investigation for restoring 
functional myocardium in a clinical setting. The first is by administering cellular signals 
and growth factors to stimulate the differentiation of recently discovered stem cells 
residing in heart tissue. The second and more understood approach is regeneration of 
cardiomyocytes through stem cell differentiation. Various protocols have been developed 
for in vivo and in vitro clinical applications using a variety of different stem cells yet 
current methodologies all possess major barriers to becoming clinically successful.  
The most attractive approach to replacing myocardial scar tissue is through 
intravenous delivery of stem cells to the target site which has shown to regenerate 
myocardium and restore function in animal models. Using an in vivo model is attractive 
for a multitude of reasons. From a clinical perspective, the procedure is minimally 
19 Image taken from mayoclinic.org
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invasive and would ideally require a series of intravenous injections. From a research 
perspective, in vivo studies provide global and regional cardiac performance benchmarks 
that would otherwise be impossible to quantify through in vitro studies. However, there 
are many significant drawbacks to in vivo studies when characterizing cell physiology. 
Current techniques for homing cells to the target site remain largely ineffective with 
many studies showing cell retention rates of less than 10%.20 In addition, once stem cells 
are incorporated into native tissue it becomes impossible to characterize cell 
differentiation on a microscopic level and thus can only gross evaluations can be made. 
Furthermore, the cost and time to perform in vivo experimentation is often exceedingly 
inconvenient and impractical for many laboratories. Thus, in vitro experimentation is 
necessary and will be the focus for the remainder of this paper.  
In vitro expansion of cells and differentiation through chemical and physical 
stimuli remain the predominant protocol for stem cell differentiation today. Cell culture 
provides greater control and handling of specimens. Additionally, gene expression of 
specific markers can be imaged and quantified. Electrical activity can be measured in 
individual cells or in spatially arranged multi-dimensional tissue structures. Cell culture is 
typically expanded on the order of 107-109 cells for seeding onto tissue scaffolds. Many 
studies over the past decade have been devoted to creating a tissue-engineered construct 
for myocardial infarct tissue replacement. There have been many challenges to date with 
developing an FDA approved myocardial construct including, cell density, cell seeding, 
and electrical viability among others.21  
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While differentiating cardiomyocytes have been effectively demonstrated in many 
stem cell lineages, many have limiting factors with current methodologies that make it 
difficult to be viable for use in a clinical approach. Various stem cells have a unique set 
of advantages and drawbacks when considering their ability to differentiate into 
cardiomyocytes and their availability using current harvesting and culturing techniques. 
1.5.2 Embryonic Stem Cells in Cardiac Tissue Engineering 
Embryonic stem cells are pluripotent cells that are derived from the inner cell 
mass of the blastocyst. Human embryos take approximately four to five days after 
fertilization to develop into the blastocyst consisting of between 50-150 cells. At this 
stage, the embryo can be sacrificed to harvest the inner cell mass for cell culture. Many 
studies including He at el have shown to differentiate embryonic stem cells into 
ventricular, atrial, nodal and purkinje-like cells making embryonic stem cells the most 
highly desirable cell type for cardiomyocyte differentiation studies. The ability to 
differentiate into any primary germ layer is the primary distinction between embryonic 
and adult stem cells. 
Embryonic stem cells possess the ability to propagate indefinitely in an 
undifferentiated state when provided the proper conditions and signals. Providing the 
proper growth factors, and cell signaling molecules, differentiation can be tailored to 
desired cell type. During early development, cells are small and spherical lacking 
myofibrils and are irregular in spatial arrangement. As maturation continues, the cells 
become elongated expressing well developed sarcomeres and myofibrils. Singular cells 
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will spontaneously beat within a week and a functional syncyctium will appear in culture 
once cellular junctions are fully developed. Additionally, electrophysiology can be 
measured at early developmental stages. Studies have shown ion channel development 
and measurable action potential readings before spontaneous beating occurs in culture 
flasks.22,23  
Zhu et al published a study in 2015 measuring the variability of over 23,000 
action potentials in embryonic derived cardiomyocytes and found that action potentials 
could be measured as early as 10 days.24 Furthermore they found between multiple 
subpopulations of cardiomyocytes within each culture displaying differences in peak to 
peak intervals between action potentials suggesting that variability in culture conditions 
may effect electrophysiology between cells of the same population. However, compared 
to other stem cell types embryonic stem cells have the least variability when compared to 
induced-pluripotent or adipose derived stem cells. This is largely due to the fact that 
differentiation of embryonic derived cardiomyocytes has been largely standardized 
compared to other stem cell lineages.25,26
Although the robust and distinguished potential of embryonic stem cell 
differentiation is the most desirable when culturing and expanding cardiomyocytes, there 
are many drawbacks in the use of these cells. There are many ethical and moral concerns 
using this cell type as the embryo must be sacrificed in order to harvest the inner cell 
mass. Federal and state level funding has historically been restricted in laboratories 
attempting to use embryonic stem cells studies. Therefore, there has been much work in 
the scientific community during the beginning of the 21st century to develop a cell line 
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that was pluripotent, yet didn’t require the sacrifice of human embryos. In 2006 a 
laboratory in Japan developed the first pluripotent stem cell derived from a human 
fibroblast which they named induced pluripotent stem cells or iPSCs 
1.5.3 Induced Pluripotent Stem Cells in Cardiac Tissue Engineering 
 
Induced pluripotent stem cells (iPSC’s) is the ideal cell type from a regenerative 
medicine standpoint. They have been shown to be pluripotent and can be derived from 
many different adult cell types. In order to induce pluripotency in a mature cell, 
introduction of four specific transcription factors must be introduced into the cell. In 2006 
Yamanaka et al showed these factors to be Sox2, Oct4, cMyc and Klf4 which were later 
named Yamanaka factors.27 Upon introduction of these transcription factors in a fully 
mature adult cell, the cell reverts back to a pluripotent or undifferentiated state that can 
then be re-differentiated into the desire cell type. Furthermore, these cells have been 
shown to proliferate indefinitely while in an undifferentiated state making them more 
attractive as a source for cardiomyocyte regeneration or other cell types under which 
undergo cell cycle arrest where proliferation is terminated in adults.28 
 
Figure 20: Reprogramming an adult cell to a pluripotent state20 
                                                
20 Image taken from mdstate.com 
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Currently the biggest setback in reprogramming cells to pluripotency is the 
efficiency using current methods. The rate at which Yamanaka’s laboratory was able to 
convert fibroblasts to a pluripotent state was estimated between 0.01-0.1% of mature 
fibroblasts used in the study. While efficiency rates have increased since, the initial study, 
conversion rates are still too low to be considered for anything other than small clinical 
and laboratory studies. 
Differentiation studies have shown iPSCs to have a very high cardiomyocyte 
development potential. However due to the broad range of methods used to induce 
pluripotency combined with variance in cell source and maintenance consistency, iPSCs 
have shown to have high phenotypic variability making some differentiation protocols 
highly efficient while others completely unsuccessful.29 Zhang et al compared the yield 
and colony populations between ESC derived cardiomyocytes and iPSC derived 
cardiomyocytes and found ESC-derived cardiomyocytes to have a higher percentage of 
spontaneously beating cells as well as having a faster beat frequency. The study also 
showed residual expression of pluipotency genes in fully developed iPSC derived 
cardiomyocytes.30 Du et al showed that action potential morphology in iPSC derived 
cardiomyocyte culture is dependent on cell seeding density further suggesting variability 
amongst studies with different seeding densities.31
As evidenced, the biggest problem with deriving cardiomyocytes using induced 
pluripotent methods is variability in the somatic cell type used as well as the 
differentiation methods. Lian et al showed that Wnt/B-catenin signaling through GSK-3 
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inhibition and suppression following mesoderm formation yielded 82-95% 
cardiomyocyte purity in 2D culture.32
Induced pluripotent stems cells have been shown to be electrically viable 
mimicking the development cycle and action potentials found in ESC derived 
cardiomyocytes. Action potentials of ventricular and pacemaker cells have been shown to 
replicate native cardiomyocyte tissues. Spontaneously beating cardiomyocytes can be 
observed in culture flasks as early as 10 days followed by a fully beating synctytium 
weeks later.33
Once standardized protocols and sourcing become more prevalent, iPSCs possess 
unique potential in becoming a clinically viable solution to many diseases. Unfortunately 
one of the largest remaining challenges is the time and resource expense to produce a 
high enough yield to be used in tissue engineering applications. Current studies have 
revealed new methods of significantly higher efficiency rates in reprogramming adult 
cells, however these protocols have been flagged as safety hazards for future clinical 
studies. Researchers at the University of Wisconsin have found that by deleting the tumor 
suppressant gene p53, adult cells have been shown to significantly increase 
reprogramming rates. These cells when expanded in culture have been shown to 
propagate at significantly increased rates that mimic cancerous cell growth. Thus a 
tradeoff currently exists between safety and efficiency which must be considered when 
evaluating the potential for iPSC use in regenerative medicine applications.34   
While iPSCs are under heavy investigation for future clinical applications 
especially for the development of non regerative tissues, the logistics of using iPSCs to 
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develop entire organs or pieces of tissue remains a enormous challenge. The time 
required to reprogram and expand the number of cells necessary to create a tissue 
engineered construct would require huge monetary costs as well as critical time that the 
patient may not have. Thus using easily harvested and abundant adult cells is increasingly 
attractive when determining candidates for cellular therapy. Researchers have turned to 
mesenchymal stem cells as a source for cellular therapies for many different treatments in 
clinical applications. While these cells lack pluripotency, researchers have been 
investigating their potential for the use of cardiac tissue engineering applications.  
1.5.4 Mesenchymal and Adipose-Derived Stem Cells in Cardiac Tissue 
Engineering 
 
Adipose derived stem cells (ASC’s) are mesenchymal stem cells (MSC’s) that can 
be found and isolated from adipose tissue. MSC’s are multipotent stromal cells that have 
the ability to differentiate into a variety, but limited, number of cell types35. MSC’s have 
commonly been known to differentiate into functional chondrocytes, osteocytes, 
adipocytes and myocytes. MSC’s are derived from the mesoderm and were originally 
found present in bone marrow. Researchers have now found MSC’s to be present in a 
variety of different tissues including adipose tissue. In fact, MSC’s are found to be 500 
times more concentrated per gram of adipose tissue than per gram of bone marrow36. 
Morphological characteristics of MSC’s include a small cell body with fibroblast like 
characteristics containing a prominent nucleus. Small amounts of Golgi apparatus, 
Endoplasmic reticulum, and mitochrondria can be found as well.  
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Interest in MSC therapy has increased significantly throughout the scientific 
community for a variety of reasons. For starters, MSC’s are abundant in adult adipose 
tissue and are easily extracted. Large quantities of ASC’s are easily extracted through a 
single procedure without the need for cell culture expansion37. Furthermore, the benefit of 
using ASC’s in a clinical setting is two-fold. First, cells can be harvested non-invasively 
compared to bone marrow extraction or other MSC population dense organs. Secondly, 
cells can be harvested from an autologous source thereby eliminating any 
immunogenicity shortcomings. In the interest of generating functional cardiomyocytes, 
ASC’s are found to have the ability to differentiate into a variety of functional cell 
lineages, including myocytes. Furthermore, ASC’s have been well documented to induce 
angiogenesis as well as containing anti-inflammatory properties.38  
Methods for inducing differentiation in ASC’s has been widely researched and 
well documented for certain cell types. As stated previously, ASC’s have been known to 
differentiate into chondrocytes, osteocytes and adipocytes with relatively little ease. This 
could be due to the fact that these cells are static cell types in which are functionally 
intended to support forces, store energy, or maintain shape of a body. In the case of 
myoblasts and more specifically cardiomyocytes, the function of these cells is more 
involved and thus differentiating into these cell lines is a more complex procedure and 
one that is difficult to reproduce in the laboratory with positive results.39
In 2004 Planat-Benard was one of the first laboratories to produce spontaneous 
beating cardiomyocytes from adipose tissue stromal cells in adult mice. They cultured the 
cells in methylcellulose culture medium along with a cocktail of supplements including 
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fetal bovine serum and 2-mercaptoethanol. Electrophysiological activity was measured 
using current clamp on a whole cell patch configuration. The adipose derived 
cardiomyocytes exhibited spontaneous electrical activity between -40 and -60 mV with 
62 millisecond intervals. The action potentials measured strongly resembled pacemaker 
cells lacking a stage two or three region in the graph. Furthermore, immunostaining 
indicated presence of alpha actinin, beta myosin heavy chain, and connexin 43 which are 
all indicative of cardiomyocyte formation.40  
 Since this journal was published, many other scientific research groups have tried 
to replicate the protocol or produce different protocols to achieve the same results. Choi 
et el reviewed many protocols involving the differentiation of ASCs using a modified 
cardiogenic media, 5-azacytidine, and trichostatin A. They also attempted to co-culture 
ASCs with rat cardiomyocytes and found the differentiated cells to possess many 
cardiomyocyte markers. However, spontaneous contraction was never achieved even 
after eight weeks of culture. Many other studies have shown that cultured and freshly 
isolated ASCs are capable of improving functional cardiac output when directly injected 
into the heart suggesting that these cells are capable of differentiating into fully 
functional cardiomyocytes. However, it remains unclear if ASCs are able to differentiate 
into pacemaker cells as many other studies have attempted to reproduce the Planat-
Bernard study unsuccessfully.41  
 Although ASCs lacks the pluripotency of other stem cells, they have great 
potential in cardiac tissue engineering. The ability to harvest these cells so quickly and 
easily makes for an excellent patient driven source for treatment. While there is still 
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much work ahead in establishing a standard protocol for isolation and culture of ASCs to 
achieve maximum cardiomyocyte yield, if perfected may be the most optimal cell for use 
in clinical setting.  
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Chapter 2: Project Aims and Rationale 
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Current treatment options for patients with varying heart ailments serve as a 
bridge to prevent further complications. There are currently no tissue engineered clinical 
solutions available to promote growth and regeneration of functional myocardium. Thus, 
there are deficiencies in current clinical treatments that need to be addressed through 
translational tissue engineering approaches. Various stem cell therapies are being 
explored and used in phase 1 clincal trials yet there are many drawbacks specific to the 
type of stem cell being used. While many studies have been able to successfully generate 
ventricular cardiomyocytes, far less have been able to generate high volumes of 
pacemaker cells that are critical in providing clinical treatments for patients with 
arrhythmias. This research was driven to provide further insight into cellular 
electrophysiology to the tissue engineering community through the following aims: 
1. Measuring electrophysiology of induced-pluripotent, embryonic and adipose
derived stem cells using various patch clamping techniques and multielectrode
arrays.
2. Determining the electrophysiological viability of adipose derived stem cells co-
cultured with differentiated embryonic derived cardiomyocytes.
3. Investigating the potential to generate pacemaker cells from adipose derived stem
cells using 3D scaffolds.
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Chapter 3: Materials and Methods 
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3.1 Cell Culture Techniques  
3.1.1 Culturing the iCell® induced-pluripotent stem cells 
Preparation of a 0.1% gelatin solution was made dissolving 100 mg of gelatin in 
100 ml of water in a sterile bottle. Sterilzation of the solution was performed by 
autoclaving the solution using the liquid cycle setting. 
Addition of 2 mL of gel solution was added to two 6-well plates and were 
incubated in 37°C for 1 hour cells were placed in a 37°C water bath for 4 minutes to 
thaw. The cell vial was dried and then sprayed with 70% ethanol and placed in a 
biosafety cabinet. The contents of the vial were then transferred to a sterile 50 mL 
centrifuge tube using a 1 mL pipette, rinsing the vial with an additional 1 mL of iCell® 
Plating Media to completely remove all cells. The media was then added dropwise to the 
50 ml centrifuge tube over the course of 90 seconds to minimize osmotic shock. Then 8 
mL of plating media was added to the centrifuge tube with the first mL added drop-wise 
for the first 60 seconds and then the remaining 7 ml over the next 30 seconds. The 
contents of the centrifuge tube were gently mixed by inversion 3 times before counting 
the cells using a cell scepter. The cell viability was measured at 1.2*106 cells per mL and 
were plated at 200,000 cells per well. Cells were incubated overnight and after 24 hours 
the plating media was exchanged with 2 mL per well of fresh iCell® Maintenance Media. 
Media was changed every other day until cells fully matured. 
3.1.2 Culturing the Cytiva™ embryonic stem cell derived cardiomyocytes in 2D 
Preparation of RPMI/B27™ medium for culture was prepared using 500 mL of 
RPMI+Glutamine medium as well as 10 mL of the B27™ supplement distributed by 
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General Electric Health. The B27™ supplement was thawed in a 37°C water bath. Upon 
removal, it was transferred to a biosafety cabinet along with the RPMI media to be 
combined and vacuum filtered for complete sterilization. In addition, 6 well plates were 
pretreated with a 1 mg per mL fibronectin solution for 2 hours at 37°C.  
Cells were thawed in a 37°C water bath with gentle agitation until ice crystals 
disappeared in the vial. Cells were immediately transferred to a 50 mL tube in the 
biosafety cabinet and an additional 1 mL of room temperature RPMI was added to the 
cryovial and then transferred dropwise to the cell suspension with gentle mixing. Over 
the course of 2 minutes, 8 additional mL of RPMI media was added to the tube to prevent 
osmotic shock. The cell suspension was then centrifuged at 300 g for 5 minutes at 20°C. 
The supernatant was removed using an aspirator and the cells were re-suspended in 6 mL 
of media. One mL of the suspension was added to each well of the pretreated 6-well 
plate. The media was changed daily and the cells were incubated at 37°C for a week 
before being used in patch clamp studies.  
3.1.3 Culturing ADSCs in a Monolayer (2D) 
The media was assembled using 500 mL of mesenPRO RS™ basal medium and 
10 mL of mesenPRO RS™ growth supplement distributed by ThermoFisher Scientific. 
The supplement was thawed in a 37°C water bath and transferred to the biosafety cabinet 
with the medium to be mixed and vacuum filtered. The container containing mixed media 
was immediately wrapped with aluminum foil as the supplement is light sensitive. 
To plate the cells, 30 mL of fresh media was transferred to a 50 mL conical tube, 
wrapped with aluminum foil and warmed to room temperature. One vial of Invitrogen 
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ADSCs concentrated at 4*106 cells per mL were thawed in a 37°C water bath for 3 
minutes until ice crystals fully melted. The cells were then transferred to a 15 mL conical 
tube and 1 mL of media was used to rinse the contents of the cryovial. Four mL of media 
was added slowly to the tube and centrifuged down at 300 g for 5 minutes. The 
supernatant was aspirated and the cells were re-suspended in 1 mL of media. In a Corning 
T-175 culture flask, 20 mL of fresh media was added along with the 1 mL of cell
suspension. Media was changed every 48 hours and the cells were passaged once 
confluent.  
For cell passaging, 6 mL of a 0.1% Gibco® trypsin-EDTA solution along with 60 
mL of fresh media was warmed in a 37°C water bath. The media from the culture flask 
was aspirated and rinsed with 20 mL of room temperature sterile PBS solution. After the 
cells were rinsed, 6 mL of the trypsin-EDTA solution was added to the culture flask and 
incubated at 37°C for 5 minutes. Once the cells were inspected under the microscope to 
confirm detachment, 12 mL of media was added to the flask to deactivate the trypsin. The 
cell suspension was pipetted 3 times to thoroughly rinse the bottom of the flask. The 18 
mL suspension was then transferred to a 50 mL tube and centrifuged at 300 g for 5 
minutes. The supernatant was aspirated and re-suspended in 6 mL of media. Two mL of 
cell suspension were then added to 3 T-175 flasks with 18 mL of media. The flasks were 
incubated at 37°C and the media changed every 48 hours.  
3.1.4 Culturing ADSCs in 3D spheroids 
To make the scaffolds, a 1% gelatin solution was made by added 1 gram of 
agarose to 100 mL of water in a beaker. The solution was heated in a microwave until 
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boiling stopping to swirl the solution every 10 seconds. Once the gelatin had completely 
dissolved, the solution was placed on a hot plate set to 70°C with a stir bar for continual 
agitation under a biosafety hood.  
A bucket filled with ice was placed in the hood upon which a Sigma-Aldrich 12-
36TO 3D Petri Dish® mold was placed. To form the gels, 500 uL of agarose gel solution 
was then pipetted into the mold and hardened over the course of three minutes. To 
remove the cast from the mold, the ends were pinched on either side and inverted above a 
clean petri dish. The gels were then placed separately in a 12 well plate and equilibrated 
with cell culture medium for 15 minutes at 37°C. This process was repeated twice to 
completely equilibrate the gel with the cell culture media. The media was then aspirated 
and the ADSCs were seeded in the cell seeding chamber at a density of 1.08*106 cells per 
gel for a final concentration of 30000 cells per sphere. The gels were incubated for 30 
minutes to allow cells to completely settle before adding 1 mL of culture media to each 
well. Cells incubated in the gels for 1 week before removal with fresh media changes 
every day.  
3.2 Patch Clamping Techniques  
3.2.1 Automated Patch Clamp Setup 
First the media was aspirated in each well that was to be used and rinsed with 
PBS twice. One mL of Sigma-Aldrich Accutase® cell detachment solution was added to 
each well and then incubated for 5 minutes at 37°C. Once cells were observed under the 
microscope to confirm that they have been lifted, an equal amount of media (~1 mL) was 
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then added to the wells to deactivate solution. The cells were then added to a 15 ml 
conical tube and were centrifuged at 1000 rpm for 3 minutes. The supernatant was 
aspirated and the pellet was re-suspended in 1 mL of fresh media.  
For this experiment, the Nanion Port-a-Patch® automated patch clamp setup was 
used and 5 mL of intracellular, extracellular and seal enhancer solutions were prepared 
beforehand shown in table 1: 
Table 1: Extracellular, intracellular and sealant compositions
The appropriate Nanion Port-a-Patch® setup is as follows and can be viewed in 
figure 21. The Port-a-Patch® is first connected via a small diameter tube to Nanion’s 
Suction Control Pro® vacuum system. In addition the Port-a-Patch® is connected to the 
HEKA EPC Patch Clamp Amplifier which is connected to a computer. For these 
experiments the HEKA PATCHMASTER data acquisition software was used in 
conjunction with this setup. For all patch clamp studies using the Nanion automated 
Internal Solutions External Solutions Seal Enhancer 
50 mM KCl 140 mM NaCl 80 mM NaCl 
10 mM NaCl 4 mM KCl 3 mM KCl 
60 mM K-Flouride 1 mM MgCl2 10 mM MgCl2
20 mM EGTA 2 mM CaCl2 35 mM CaCl2
10 mM Hepes 5 mM D-glucose 
monohydrate 
10 mM Hepes 
285 mOsmol, pH 7.2 10 mM Hepes 285 mOsmol pH 7.2 
298 mOsmol, pH 7.2 
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system, NPC®-1 chips were used which contain a borosilicate glass slide with varying 
micron sized apertures. For the majority of the experiments, the 5 MOhm chips were used 
as the size of the iPSCs and ESCs most appropriately suited the chip diameter.  
Figure 21: Nanion Port-a-Patch Setup 
3.2.2 Suspending the Cells onto the Microchip 
Cells were suspended onto the chip using the prepared solutions as follows. First, 
5 uL of intracellular solution was placed on the inside well of the microchip. The top 
plate of the Port-a-Patch is removed and the chip is screwed into place accordingly as 
illustrated in figure 22. The cap was replaced and 5 uL of extracellular fluid was pipetted 
on top of the microchip being sure that the extracellular lead contacts the fluid. The 
vacuum is then applied to exert positive pressure on the solution to prevent 
contamination. Five microliters of cell suspension is then immediately and forcefully 
pipetted to the extracellular solutions to provide a downward force by which the cells will 
gravitate to the bottom of the chip. Once a cell comes into contact with a hole on the chip, 
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the resistance will increase between the cell membrane and the chip. Upon seeing a spike 
in the resistance value outputted by the software, 15 uL of enhancer solution is added 
until a tight seal forms between the cell and the chip. The seal enhancer is replaced with 
extracellular fluid following a gigaohm seal and the vacuum is increased incrementally 
until the cell membrane is compromised. Upon rupturing the cell membrane, current 
clamp and voltage clamping experiments were performed for each cell type.  
Figure 22: Microchip setting and placement 
3.2.3 Experimental Parameters for Electrophysiology Studies 
To perform voltage or current clamp experiments, the cell must be stimulated 
with either current or voltage above the membrane potential. The tables below list all 
essential parameters that were input into the Patch Master software for each 
corresponding study.  
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Table 2 iPSC study input parameters 
Table 3: ESC study input parameters 
Table 4: ADSC co-culture study parameters 
iCell	  iPSC	  Study	  
Sample	  1	   Sample	  2	   Sample	  3	   Sample	  4	  
Configuration	  
Voltage	  
Clamp	  
Current	  
Clamp	  
Current	  
Clamp	  
Current	  
Clamp	  
Input	  
Voltage/Current	   -­‐140	  mV	   -­‐40	  mA	   -­‐40	  mA	   10	  mA	  
Increments	   10	  mV	   15	  mA	   15	  mA	   15	  mA	  
Number	  of	  Sweeps	   20	   4	   4	   4	  
Sample	  Interval	   200	  us	   200	  us	   200	  us	   200	  us	  
Sweep	  Interval	   5	  s	   15	  s	   15	  s	   15	  s	  
Cytiva®	  ESCs	  Study	  
Sample	  1	   Sample	  2	   Sample	  3	   Sample	  4	  
Configuration	  
Current	  
Clamp	  
Current	  
Clamp	  
Current	  
Clamp	  
Current	  
Clamp	  
Input	  
Voltage/Current	   -­‐45	  mA	   -­‐45	  mA	   -­‐60	  mA	   -­‐90	  mA	  
Increments	   15	  mA	   15	  mA	   15	  mA	   15	  mA	  
Number	  of	  Sweeps	   4	   4	   4	   4	  
Sample	  Interval	   200	  us	   200	  us	   200	  us	   200	  us	  
Sweep	  Interval	   15	  s	   15	  s	   15	  s	   15	  s	  
ESC-­‐ADSC	  Co-­‐Culture	  Study	  
Sample	  1	  
Configuration	   Current	  Clamp	  
Input	  Voltage/Current	   -­‐45	  mA	  
Increments	   15	  mA	  
Number	  of	  Sweeps	   8	  
Sample	  Interval	   200	  us	  
Sweep	  Interval	   15	  s	  
58 
3.3 Multielectrode Array Techniques 
For this study, model Multichannel systems 60MEA200/30iR-ITO chips were 
used along with a Multichannel systems MEA 1060 Amplifier and Data Acquisition 
Module. Cytiva® MEAs were autoclaved at 110°C for 30 minutes and ESCs were 
thawed as described in section 3.1.2 and plated in 2 MEAs treated with fibronectin at 
200,000 cells per MEA. The cells were incubated over the course of a week changing the 
media once every 24-hours. Once cells were observed spontaneously contracting the 
MEAs were recorded for electrophysiological readings. To read the MEAs they are set 
within the amplifier matching the ground electrode on the plate to the grounded pin on 
the amplifier. The MEA is then firmly mounted into place by pressing the top half of the 
amplifier down into the pins on the bottom half of the amplifier. The amplifier is then set 
within a metal cage to prevent signal noise during recording. The plates were sampled at 
5 kHz and still frame and full motion videos of electrophysiological activity were taken.  
3.4 Differentiation Methods of ADSCs 
3.4.1 Differentiation of ADSCs in 2D Co-Culture 
ADSCs and ESCs were cultured as described in sections 3.1.2 and 3.1.3 
respectively. A 12-well plate was divided into 3 groups of 4 samples each, the groups are 
as follows: ADSC, ESC and ADSC-ESC co-culture. The ADSC group was seeded at a 
density of 200,000 cells per well, the ESC group was seeded at 200,000 cells per well and 
the co-culture group was seeded at a 1:2 ratio (60,000 ESCs per well to 120,000 ADSCs 
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per well). The cells were incubated at 37°C for one week before performing patch clamp 
recording. The parameters used for this study are shown in table 4.  
3.4.2 Differentiation of ADSCs in 3D Spheroids 
ADSCs were cultured and seeded in agarose gels as described in section 3.1.4. 
Cells were incubated undisturbed in the scaffolds for 48 hours after which the cells were 
removed. Removal of the spheres required inverting each gel and gently tapping the side 
of the 6-well plate to loosen the cells from the wells. Then, each scaffold was rinsed 
repeatedly with PBS to completely dislodge the cells from the molds. Once all the 
spheroids were removed from the wells, the gels were discarded and the spheroids were 
transferred evenly in four collagen type 1 coated Flexcell BioFlex® culture plates. These 
are specialized plates that contain rubber surface membranes for delivered mechanical 
load regimens to the cell culture. Each plate corresponds to a different method of 
differentiation as follows: Mechanical stimuli, chemical stimuli, mechanical and 
chemical stimuli, as well as a non-stimulus control group. All groups were differentiated 
in RPMI+Glutamine media with 10% Bovine growth serum and 1% antibiotic. Chemical 
differentiation groups were additionally treated using 5-Azocytidine at a concentration of 
10 uM/well for 24 hours.  
3.5 Flexcell® Bioreactor Experimental Setup and Software Configuration 
Mechanical stimuli was administered using the Flexcell FX-5000™ Tension 
system. The system held the culture plates into place using the BioFlex® Loading 
Stations™ with 25 mm loading posts as pictured in figure 23.  
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Figure 23: Flexcell culture plates mounted in the loading station 
To position the plates, a petroleum jelly is swabbed along the interior of baseplate 
rim and the plates are pressed into the depression. The Bioflex® Baseplates were placed 
at the bottom and top of the loading station and mounted into place using screws. The 
baseplate is then connected via vacuum tubing to the FX5K™ Tension FlexLink® a 
remote tension or compression unit that is connected to a desktop computer shown in 
figure 24. The baseplate was placed in a standard incubator at 37°C for 4 days. The 
software used to run the flexcell system is called the Flexcell® FX-5000 software. The 
parameters were set to administer a positive pressure of 120 mmHg every second 
(equivalent to 60 beats per minute).   
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Figure 24: Flexcell FX-5000 setup 
3.6 Immunoflorescent Cell Staining and Imaging 
After 10 days of incubation the spheroids were rinsed with PBS and fixed with 
4% paraformaldehyde for 20 minutes at room temperature. The paraformaldehyde was 
aspirated and the cells were rinsed with PBS 3 times. The cells were permeabilized with 
0.3% triton in PBS for 10 minutes at room temperature. BSA concentrated at 0.5% along 
with 0.5% triton was used to block the cells for 1-2 hours to prevent any non-specific 
binding. Alexa Flour® primary rabbit antibody was used in a 1:1 ratio with the blocking 
solution which was pipetted onto the cells. The samples were placed on an orbital shaker 
for 2 hours at room temperature. The samples were rinsed with PBS 3 times before 
proceeding with the secondary antibodies. 
To stain for Cx-43, Alexa Flour® mouse anti-rabbit secondary antibodies were 
diluted 1:100 and added to the 1:1 blocking solution at 4 uL per mL. Desmin Alexa 
Flour® mouse anti-rabbit antibodies were diluted to 1 uL per mL and then added to the 
blocking solution at 4 uL per mL. Approximately 500 uL of the antibody solution was 
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then added to the wells and covered with aluminum foil on an orbital shaker for 1 hour at 
room temperature. The samples were imaged using a fluorescent microscope at 10X 
magnification.  
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Chapter 4: Results and Discussion 
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4.1 Study 1: Measuring Action Potentials in iCell® Cardiomyocytes 
In this study both current clamp and voltage clamp configurations were used. The 
electrophysiological readings of the voltage clamp configuration can be seen in figure 25 
which corresponds to sample 1 in table 2. The first feature present in the graph is what 
appears to be an artifact at the 100 ms tick in the graph. This blip is a capacitive transient 
current which appears when the membrane immediately experiences a change in polarity 
when exposed to a stepwise voltage increase. 
Once an immediate change in polarity occurs, a strong negative current follows 
due to the large sodium ion influx. Potassium channels open thereafter which accounts 
for the repolarization. This sample was recorded three days post plating and it is likely 
that ion channels were not fully matured yet resulting in an inability to perform current 
clamp recordings thus, samples were re-recorded 10 days post plating.  
Figure 25: Action potential of iPSC using voltage clamp configuration 
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After seven days the samples were rerecorded using the same setup as before. 
Action potentials were measured and are shown in figures 26-28 corresponding to 
samples 2-4 in table 2.  
Figure 26: First sample action potential of iPSC 
Figure 27: Second sample action potential of iPSC 
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Figure 28: Third sample of action potential of iPSC containing sealant fluid 
The graphs seen in figures 26-28 all resemble physiological relevant action 
potentials. Each was stimulated over the course of 1 second and each action potential was 
recorded within a 200 ms interval. The first sample shown in figure 25 appears to be a 
non-spontaneous cardiomyocyte due to the resting memebrane potential being below -80 
mV. Conversely, based on the action potential displayed in figure 26, this cardiomyocyte 
could be a pacemaker cell as the resting membrane potential lies above 75. It is important 
to point out that the scales in each of the graphs are slightly different which would result 
in varying peak shapes. While there were not enough samples to conclusively distinguish 
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  80.0 mV
120. mV
100. ms 300. ms 500. ms 700. ms 900. ms
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action potentials of pacemaker compared to ventricular cardiomyocytes, it is possible that 
each were measured.  
The last graph was measured without removing the seal enhancer solution. This 
solution contains a high calcium concentration, explaining why the peak in figure 28 is 
much broader than the previous graphs as calcium causes sustained contraction in 
myocytes. 
4.2 Study 2: Measuring Action Potentials in Cytiva® Cardiomyocytes 
The action potentials measured in the following graphs all strongly resemble the 
action potentials measured from the iPSCs. All graph parameters can be viewed in the 
corresponding tables. The graphs shown in figures 29-32 were all stimulated with enough 
current to produce a complete action potential. However, in figure 31, measurements of 
early stage action potentials recorded.  
Figure 29: First sample of action potential in a ESC 
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Figure 30: Second sample of action potential in a ESC 
Figure 31: Premature action potentials in a ESC 
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Figure 32: Action potential of ESC with added calcium and cesium 
 
 In figure 31 calcium and cesium chloride was added to the extracellular fluid. The 
calcium would explain the increased peak interval while the addition of cesium likely 
explain the hyperpolarization region expressed around 600 ms. Since potassium channels 
are blocked, a higher concentration of sodium will leave the cell resulting in a brief 
hyperpolarized region.  
4.3 Study 3: Measuring Action Potentials in 2D Co-Cultures 
 
 Unfortunately for this study only one measurement was recorded. Both the ESC 
and ADSC groups could not be measured. However, one sample was recorded in the co-
culture group as show in figure 33. 
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Figure 33: 2D co-culture action potential sample 
The resting membrane potential is around -60 mV which suggests that this could 
be a pacemaker cell. Additionally, the beginning stages of a full action potential are 
shown as the cell initially was stimulated below the voltage at which a complete action 
potential is produced. This is likely an ESC being measured in this sample as none of the 
ASC samples showed any signs of containing pacemaker cells. This graph also looks 
very similar to figure 32 in which the cell was stimulated just enough to produce the 
beginnings of a full action potential.  
It is unknown why recordings were unsuccessful in the other groups. Perhaps the 
cells adhered and clumped together after removal from the flask. When cells aggregate in 
solution it prevents them from sitting properly on the chip and forming a high resistance 
seal making patch clamp recording impossible. Furthermore, the cells become less viable 
electrically when suspended for prolonged periods in suspension. It is likely that as the 
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number of failed attempts increases, the probability of a successful attempt decreases as 
the elapsed time between each sample takes approximately 5 minutes and could be 
significantly prolonged if electrophysiological measurements are being recorded.  
4.4 Study 4: Measuring Electrophysiology of Cardiomyocytes using MEA 
Unlike patch clamp, the electrophysiology recordings of the MEA looks much 
different and does not produce a similar action potential graph as a result of measuring 
the extracellular field potential. Since MEA does not involve breaking into the cell, the 
electrodes can only measure the minute changes in ion concentration in the local 
extracellular area. Thus, action potential recordings are shown as sharp peaks in the graph 
where a change in ion flow can be detected.  
In addition, many of the action potentials viewed in the subplots are different 
depending on the location of the cell relative to the electrode. Cells that are directly 
placed above an electrode and are tightly bound to the surface of the chip are likely to 
produce a much stronger action potential. Furthermore, the type of media used will have 
an impact on electrophysiological recordings, as media with higher conductivity or 
homogeneity will allow for better ion movement and thus more accurate recordings.  
The first two figures are subplots of all the electrodes measured, each electrode 
corresponding to a different subplot. Many of the subplots show no activity due to the 
absence of cells over the electrode. Furthermore, some cells could be seen directly over 
some electrodes while some cells barely came into contact with other electrodes, 
resulting in varying sized peaks displayed in the figures. The difference between figures 
34 and 35 are the scale sizes where the peaks are enlarged in figure 35. 
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Figure 34: Action potential recordings of ESCs on all electrodes on MEA 
Figure 35: Action potential recordings of ESCs on all electrodes of MEA 
Individual action subplots were expanded and enlarged in figures 35 and 36 with 
the only difference being scale size. The action potential in peaks in figure 35 at about 
350 uV and hyperpolarizes to about -100 uV. If sampling rates were increased, it is 
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possible that the action potentials in this study might resemble those taken using patch 
clamp. While the shape of the graph could have been altered by increasing the sampling 
rate, the magnitude of the peaks would still remain significantly less than what is seen 
using patch clamp due to factors discussed previously. Furthermore, these readings prove 
that the cells cultured on each of the MEA plates contained cardiac pacemaker cells as 
the samples must be self-excitable in order to produce a spontaneous voltage that can be 
recorded.   
  Figure 36: Action potential generated at a single electrode 
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Figure 37: Action potential shown at a single electrode 
4.5 Study 5: ADSC Differentiation using 3D Spheroids 
Both automated and traditional whole cell patch clamp was attempted on the 3D 
spheroids however limitations in the patch clamp configurations used for this experiment 
prevented measuring any electrophysiological activity. Therefore, we imaged the 
spheroids and measured for two specific myocyte markers using immunofluorescence. 
Samples were stained for connexin-43 and desmin which are unique cardiomyocyte 
markers. Light microscopy images were also taken of each sample group 3 days post 
plating to view the cell spreading potential of these spheroids which can be seen in 
figures 38-41.  
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Figure 38: ADSC spheroid 3 days post plating treated with mechanical stimuli 
 
 
Figure 39: ADSC spheroid 3 days post plating treated with mechanical stimuli and AZT 
 
 
 
 
Figure 40: ADSC spheroid 3 days post plating treated with AZT 
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Figure 41: Static untreated spheroid 3 days post plating 
Immunoflorescence images can be viewed in figures 42-49. The DAPI stain 
fluoresces blue and stains the cell nuclei. The Cx-43 and desmin were stained in each 
group using a fluorophore which excites at 488 nm producing a green light.  
Figure 42: ADSC derived spheroid stained for Cx-43, mechanical group 
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Figure 43: ADSC derived spheroid stained for Desmin, mechanical group 
Figure 44: ADSC derived spheroid stained for Cx-43, Mechanical+AZT group 
Figure 45: ADSC derived spheroid stained for desmin, mechanical+AZT group 
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Figure 46: ADSC derived spheroid stained for Cx-43, AZT group 
 
 
 
Figure 47: ADSC derived spheroid stained for desmin, AZT group 
 
 
 
Figure 48: ADSC derived spheroid stained for Cx-43, control group 
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Figure 49: ADSC derived spheroid stained for desmin, control group 
As shown in figures 41-48, every image contained either desmin or Cx-43 
respectively. Some pictures appear to contain more cardiac markers than others but that 
could be due to some images containing spheroids while others were planar cells. Since 
the spheroids are highly concentrated regions of cells, the proteins may appear to be more 
visible in these areas.  
The abundant expression of cardiomyocyte markers in the static groups compared 
to other groups is unexpected. It was hypothesized that groups exposed to mechanical and 
chemical stimulation would appear to express more Cx-43 and desmin than the control 
groups since stem cells cultured similarly to the native physiological environment of the 
target cell have shown to more completely differentiate. However, it is not unreasonable 
to assume that the control groups would contain these markers as it has been shown that 
differentiating ADSCs in 3D spheroids have been shown to produce myocyte like cells. It 
is probable that these cells did not fully differentiate into mature cardiomyocytes. 
 80 
Furthermore, since ADSCs are harvested from human lipo-aspirate, it is possible that the 
ADSCs contained impurities or other cells resulting in positive staining.   
Given the presence of gap junctions in these cells it is likely that they would be 
able to propagate an electrical signal however it no pacemaker activity was observed 
during the course of this experiment. If patch clamp could have been performed, it is 
likely that under stimulation, these cells could have produced an action potential 
resembling that of a ventricular cardiomyocyte. Future studies could focus on measuring 
the electrophysiology of 3D ADSC cultures using the appropriate set up.   
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Chapter 5: Conclusion and Future Directions 
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The first study using iPSCs was very successful in measuring action potentials 
using both current and voltage clamp configurations. Cells were spontaneously 
contracting after 10 days and action potentials recorded in this study matched those found 
in literature. Similarly, the second study measuring action potentials in ESCs was also 
very successful as additional current clamp measurements of premature action potentials 
were recorded as well as fully developed action potentials.  
The 2D cell co-culture using ADSCs and ESCs had some success although the 
results were inconclusive. While action potentials were recorded in the co-culture group, 
no electrophysiological readings could be measured in the ESC or ADSC single culture 
groups. Since groups containing ESCs were beating spontaneously, the action potential 
recorded in the co-culture group was likely an ESC. Additionally, many of the ADSCs 
detached from the culture resulting in an insufficient density for using the automated 
patch clamp.  
Unfortunately the 3D spheroid study was unsuccessful in measuring any electrical 
activity however immunofluorescence suggested that the cells began maturing into 
cardiomyocytes. While it remains inconclusive if the cells had fully developed into 
ventricular cardiomyocytes, it can be stated with certainty that none of the samples 
contained mature pacemaker cells as spontaneous contraction was never observed. 
Lastly, the MEA study confirmed the results from the ESC patch clamp 
experiment in that the ESCs formed spontaneously beating colonies where ion 
concentration fluctuations could be measured without any external stimulus.  
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Continuing to investigate the electrophysiological potential for differentiated stem 
cells is integral is finding a translational tissue engineered approach to various heart 
diseases. The studies shown here indicate that currently iPSCs and ESCs are the most 
viable sources for obtaining high densities of cardiac pacemaker cells. Conversely, 
spontaneous contractile activity was not observed is studies where ADSCs are solely 
used. While showing the electrophysiological potential of ADSC derived cardiomyocytes 
is well documented, culturing pacemaker cells from ADSCs is still controversial and 
more research is needed to develop a reproducible protocol for such.  
Although using current techniques it remains difficult to produce a high volume 
of pacemaker cells using ADSCs, they remain of high interest throughout the scientific 
community due to their availability. While the experiments presented in this thesis were 
limited by time and resources, there are many more possible directions that these studies 
could continue.  
Using spheroids to differentiate ADSCs into cardiomyocytes is extremely difficult 
when performing patch clamp. Thus using the same parameters and methods, a 2D 
differentiation study using ADSCs would be more convenient in testing the capability of 
these cells to contract if provided an appropriate stimulus. Furthermore, providing an 
electrical stimulus to ADSCs in culture may be a crucial element in deriving pacemaker 
cells. Using a coupled mechanical and electrical stimulus would be optimal as it is 
physiologically relevant and is recommended for future studies.  
To derive higher volumes of pacemaker cells many studies have suggested that 
seeding densities need to be optimized. Unfortunately many of the studies presented here 
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were limited by the amount of cells available at the time, thus seeding densities were 
oftentimes less than the recommended values. Further insight into varying the cell density 
in culture may result in a higher percentage of pacemaker cells, which would be 
necessary when developing a tissue engineering solution to cardiac arrhythmias. 
In addition to 5-azacytodine, many studies including Planat-Bernard have shown 
using 2-metocaptoethanol has been shown to be very successful in differentiating ADSCs 
into pacemaker cells. Future studies could compare the efficacy of cardiac differentiation 
by comparing groups of 5-azacytidine and 2-mercaptoethanol treated ADSCs. Varying 
the concentration of these groups is also important in determining an optimal 
concentration as too much may damage the DNA while too little would result in 
insufficient inhibition of DNA methylation.  
While the work that was presented here was successful in confirming the capacity 
for iPSCs and ESCs to differentiate into spontaneously beating cardiomyocytes, it was 
inconclusive in determining the cardiomyocyte differentiating ability for ADSCs to 
generate. Unfortunately due to the limitations of time and resources many other studies 
that could elucidate more on ADSC differentiation were beyond the scope of this project. 
Future studies should continue to work on finding ways to better differentiate ADSCs 
into pacemaker cell in vitro for use in clinical applications.  
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